Eli Lilly and Company

Latest Eli Lilly and Company news and discussion

Sort by

Content type

Eli Lilly and Company· Health · 8 sources · Oct 2, 2026Story

FDA expands Lilly Jaypirca approval after 80% risk reduction in untreated CLL

On Oct. 2, 2026 the FDA expanded Lilly’s Jaypirca to first-line CLL/SLL without 17p deletion after BRUIN CLL-313 showed an 80% cut in progression or death risk.

Health· Oct 2, 2026

+5

+32Share

Dana Whitfield·Oct 3, 2026Top commentI hope the expanded use leads to better access overall, though real-world results and side effect management will matter just as much as the trial numbers.

ReplyGenius replyShare

Write a comment…

Eli Lilly and Company· Business · 10 sources · Sep 21, 2026Story

Eli Lilly Breaks Ground on $6.5B Houston Facility

Eli Lilly broke ground Sept. 21, 2026 on a $6.5B Houston API plant to make Foundayo, its oral GLP-1 pill, with 600+ jobs as part of a $50B U.S. manufacturing push.

Business· Sep 21, 2026

+7

+23Share

Maya Lindstrom·Sep 22, 2026Top commentHope this oral GLP-1 pill becomes more affordable once production ramps up locally.

ReplyGenius replyShare

Write a comment…

Eli Lilly and Company· Business · 9 sources · Sep 24, 2026Story

InnoCare and Lilly Sign Drug Discovery Deal With Up to $3.25 Billion in Milestones

InnoCare shares fell after announcing a pact with Eli Lilly worth up to $3.25 billion in milestones covering as many as five drug targets.

Business· Sep 24, 2026

+6

+32Share

Tom Gallagher·Sep 24, 2026Top commentLilly is betting big on InnoCare's platform with those billions in milestones, but execution will decide if it pays off.

ReplyGenius replyShare

Write a comment…

Eli Lilly and Company· Health · 1 source · Oct 21, 2026Story

The FDA Already Drew Line On China-Linked Experimental Drug. Now It Has To Enforce It

In July, a 41-year-old woman went into cardiac arrest after taking retatrutide that a health care worker said came from an "unreliable source."

Health· Oct 21, 2026

0CommentShare

Write a comment…

Eli Lilly and Company· Health · 9 sources · Oct 19, 2026Story

METiS, Lilly Sign Up-to-$1.1B AI Drug Delivery Deal

Hong Kong-based METiS TechBio and Eli Lilly will collaborate on AI-designed lipid nanoparticles to deliver medicines to specific tissues, with Lilly handling further development and commercialization. METiS could receive up to about $1.1 billion in milestone payments plus royalties, but no targets or resulting drug candidates have been disclosed.

Health· Oct 19, 2026

+6

0CommentShare

Write a comment…

Eli Lilly and Company· Business · 16 sources · Sep 14, 2026Story

Novo Nordisk Rebrands as Novo While Fighting for Obesity Market Share

On Sept. 14, 2026, Novo Nordisk said it will operate as Novo; NVO fell about 2.14% that day and roughly 15% YTD, with 38.8% obesity share versus Lilly's 60.9%.

Business· Sep 14, 2026

+13

+31Share

Marcus Bell·Sep 14, 2026Top commentRebranding to just Novo feels like a distraction when their obesity share has already slipped to 38 percent against Lilly.

ReplyGenius replyShare

Write a comment…

Eli Lilly and Company· Business · 5 sources · Sep 1, 2026Story

Novo Nordisk launches Wegovy pill in Germany as Eli Lilly readies rival

Novo Nordisk is rolling out Wegovy as an oral weight‑loss pill in Germany, the EU’s first market to receive the formulation after EU approval, with prices expected around €170–€280 and strong competition from Eli Lilly’s Foundayo on the horizon. The launch leverages Wegovy’s dominant position in the oral obesity market, while analysts weigh the impact of the tablet on growth, pricing, and payer access across Europe.

Business· Sep 1, 2026

+2

+23Share

Tom Gallagher·Sep 2, 2026Top commentCurious how many insurers in Germany will actually cover this at launch, oral obesity meds still feel like they're priced for a niche market.

ReplyGenius replyShare

Write a comment…

Eli Lilly and Company· Health · 7 sources · Oct 16, 2026Story

Lilly, Roche plan Alzheimer’s blood screening in Korea

Eli Lilly and Roche Diagnostics are partnering to expand the use of blood-based biomarkers in South Korea to identify patients who may need confirmatory Alzheimer’s testing, potentially easing access to diagnosis before more costly PET scans or spinal-fluid tests. Experts also emphasize that amyloid PET imaging can confirm disease pathology and help guide use of anti-amyloid treatments.

Health· Oct 16, 2026

+4

0CommentShare

Write a comment…

Eli Lilly and Company· Business · 12 sources · Aug 31, 2026Story

Lilly's $2.9B deal adds treatments for Graves' disease and food allergies

Eli Lilly is acquiring Merida Biosciences for about $2.88 billion in cash, expanding its immunology and allergic-disease pipeline beyond its obesity drugs, with the deal expected to close in Q4 2026 and marking Lilly’s ongoing aggressive M&A strategy. Merida’s lead program MER511 targets Graves’ disease and thyroid eye disease, while MER769 is in preclinical development for food allergy, asthma and chronic spontaneous urticaria, underscoring a broadened portfolio as Lilly references roughly $29 billion in upfront and milestone payments this year across acquisitions.

Business· Aug 31, 2026

+9

0CommentShare

Write a comment…